Nevertheless, ILD continues to take some of the shine off the efficacy results generated with Daiichi Sankyo's ADC candidates. HER3 is expressed in more than 80% of EGFR-mutant NSCLC, and ...
Breast cancer data Now, Daiichi Sankyo has been able to show signs of efficacy for the ADC beyond lung cancer, with the first data from a phase 1/2 study in patients with HER3-positive metastatic ...
Hosted on MSN2mon
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mUnder that agreement, Daiichi Sankyo gained exclusive global rights to develop and commercialise gatipotuzumab as an antibody-drug conjugate (ADC ... ADCs targeting HER3, B7-H3, and CDH6.
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...
Zacks.com on MSN2mon
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast CancerThe drug, developed in partnership with Japan-based Daiichi Sankyo, will be marketed under the brand name Datroway. Post the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback